Cargando…
Improved immunogenicity of Newcastle disease virus inactivated vaccine following DNA vaccination using Newcastle disease virus hemagglutinin-neuraminidase and fusion protein genes
The present study describes the development of DNA vaccines using the hemagglutinin-neuraminidase (HN) and fusion (F) genes from AF2240 Newcastle disease virus strain, namely pIRES/HN, pIRES/F and pIRES-F/HN. Transient expression analysis of the constructs in Vero cells revealed the successful expre...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Korean Society of Veterinary Science
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4808640/ https://www.ncbi.nlm.nih.gov/pubmed/27051336 http://dx.doi.org/10.4142/jvs.2016.17.1.21 |
_version_ | 1782423498315005952 |
---|---|
author | Firouzamandi, Masoumeh Moeini, Hassan Hosseini, Davood Bejo, Mohd Hair Omar, Abdul Rahman Mehrbod, Parvaneh Ideris, Aini |
author_facet | Firouzamandi, Masoumeh Moeini, Hassan Hosseini, Davood Bejo, Mohd Hair Omar, Abdul Rahman Mehrbod, Parvaneh Ideris, Aini |
author_sort | Firouzamandi, Masoumeh |
collection | PubMed |
description | The present study describes the development of DNA vaccines using the hemagglutinin-neuraminidase (HN) and fusion (F) genes from AF2240 Newcastle disease virus strain, namely pIRES/HN, pIRES/F and pIRES-F/HN. Transient expression analysis of the constructs in Vero cells revealed the successful expression of gene inserts in vitro. Moreover, in vivo experiments showed that single vaccination with the constructed plasmid DNA (pDNA) followed by a boost with inactivated vaccine induced a significant difference in enzyme-linked immunosorbent assay antibody levels (p < 0.05) elicited by either pIRES/F, pIRES/F+ pIRES/HN or pIRES-F/HN at one week after the booster in specific pathogen free chickens when compared with the inactivated vaccine alone. Taken together, these results indicated that recombinant pDNA could be used to increase the efficacy of the inactivated vaccine immunization procedure. |
format | Online Article Text |
id | pubmed-4808640 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | The Korean Society of Veterinary Science |
record_format | MEDLINE/PubMed |
spelling | pubmed-48086402016-04-05 Improved immunogenicity of Newcastle disease virus inactivated vaccine following DNA vaccination using Newcastle disease virus hemagglutinin-neuraminidase and fusion protein genes Firouzamandi, Masoumeh Moeini, Hassan Hosseini, Davood Bejo, Mohd Hair Omar, Abdul Rahman Mehrbod, Parvaneh Ideris, Aini J Vet Sci Original Article The present study describes the development of DNA vaccines using the hemagglutinin-neuraminidase (HN) and fusion (F) genes from AF2240 Newcastle disease virus strain, namely pIRES/HN, pIRES/F and pIRES-F/HN. Transient expression analysis of the constructs in Vero cells revealed the successful expression of gene inserts in vitro. Moreover, in vivo experiments showed that single vaccination with the constructed plasmid DNA (pDNA) followed by a boost with inactivated vaccine induced a significant difference in enzyme-linked immunosorbent assay antibody levels (p < 0.05) elicited by either pIRES/F, pIRES/F+ pIRES/HN or pIRES-F/HN at one week after the booster in specific pathogen free chickens when compared with the inactivated vaccine alone. Taken together, these results indicated that recombinant pDNA could be used to increase the efficacy of the inactivated vaccine immunization procedure. The Korean Society of Veterinary Science 2016-03 2016-03-22 /pmc/articles/PMC4808640/ /pubmed/27051336 http://dx.doi.org/10.4142/jvs.2016.17.1.21 Text en © 2016 The Korean Society of Veterinary Science. http://creativecommons.org/licenses/by-nc/4.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Original Article Firouzamandi, Masoumeh Moeini, Hassan Hosseini, Davood Bejo, Mohd Hair Omar, Abdul Rahman Mehrbod, Parvaneh Ideris, Aini Improved immunogenicity of Newcastle disease virus inactivated vaccine following DNA vaccination using Newcastle disease virus hemagglutinin-neuraminidase and fusion protein genes |
title | Improved immunogenicity of Newcastle disease virus inactivated vaccine following DNA vaccination using Newcastle disease virus hemagglutinin-neuraminidase and fusion protein genes |
title_full | Improved immunogenicity of Newcastle disease virus inactivated vaccine following DNA vaccination using Newcastle disease virus hemagglutinin-neuraminidase and fusion protein genes |
title_fullStr | Improved immunogenicity of Newcastle disease virus inactivated vaccine following DNA vaccination using Newcastle disease virus hemagglutinin-neuraminidase and fusion protein genes |
title_full_unstemmed | Improved immunogenicity of Newcastle disease virus inactivated vaccine following DNA vaccination using Newcastle disease virus hemagglutinin-neuraminidase and fusion protein genes |
title_short | Improved immunogenicity of Newcastle disease virus inactivated vaccine following DNA vaccination using Newcastle disease virus hemagglutinin-neuraminidase and fusion protein genes |
title_sort | improved immunogenicity of newcastle disease virus inactivated vaccine following dna vaccination using newcastle disease virus hemagglutinin-neuraminidase and fusion protein genes |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4808640/ https://www.ncbi.nlm.nih.gov/pubmed/27051336 http://dx.doi.org/10.4142/jvs.2016.17.1.21 |
work_keys_str_mv | AT firouzamandimasoumeh improvedimmunogenicityofnewcastlediseasevirusinactivatedvaccinefollowingdnavaccinationusingnewcastlediseasevirushemagglutininneuraminidaseandfusionproteingenes AT moeinihassan improvedimmunogenicityofnewcastlediseasevirusinactivatedvaccinefollowingdnavaccinationusingnewcastlediseasevirushemagglutininneuraminidaseandfusionproteingenes AT hosseinidavood improvedimmunogenicityofnewcastlediseasevirusinactivatedvaccinefollowingdnavaccinationusingnewcastlediseasevirushemagglutininneuraminidaseandfusionproteingenes AT bejomohdhair improvedimmunogenicityofnewcastlediseasevirusinactivatedvaccinefollowingdnavaccinationusingnewcastlediseasevirushemagglutininneuraminidaseandfusionproteingenes AT omarabdulrahman improvedimmunogenicityofnewcastlediseasevirusinactivatedvaccinefollowingdnavaccinationusingnewcastlediseasevirushemagglutininneuraminidaseandfusionproteingenes AT mehrbodparvaneh improvedimmunogenicityofnewcastlediseasevirusinactivatedvaccinefollowingdnavaccinationusingnewcastlediseasevirushemagglutininneuraminidaseandfusionproteingenes AT iderisaini improvedimmunogenicityofnewcastlediseasevirusinactivatedvaccinefollowingdnavaccinationusingnewcastlediseasevirushemagglutininneuraminidaseandfusionproteingenes |